CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy-Reference-Cited by-同舟云学术

CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy

Published:2019-11-18 Issue:22 Volume:3 Page:3539-3549
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Pillai Vinodh¹^ORCID,Muralidharan Kavitha²,Meng Wenzhao¹,Bagashev Asen¹,Oldridge Derek A.¹^ORCID,Rosenthal Jaclyn²^ORCID,Van Arnam John¹,Melenhorst Jos J.¹,Mohan Diwakar³^ORCID,DiNofia Amanda M.⁴,Luo Minjie¹^ORCID,Cherian Sindhu⁵,Fromm Jonathan R.⁵,Wertheim Gerald¹,Thomas-Tikhonenko Andrei¹^ORCID,Paessler Michele¹,June Carl H.¹,Luning Prak Eline T.¹^ORCID,Bhoj Vijay G.¹^ORCID,Grupp Stephan A.⁴,Maude Shannon L.⁴,Rheingold Susan R.⁴

Affiliation:

1. Department of Pathology and Laboratory Medicine and

2. Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA;

3. Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD;

4. Division of Oncology, Cancer Immunotherapy Program, Children's Hospital of Philadelphia, Philadelphia, PA; and

5. Department of Laboratory Medicine, University of Washington, Seattle, WA

Abstract

Key Points Preinfusion dim CD19 expression and rare CD19– events in B-ALL do not affect relapses or responses to CD19-directed CAR T-cells. Prior blinatumomab treatment increases the rate of failure to achieve MRD– remission and CD19– MRD and relapse.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/3/22/3539/1540328/advancesadv2019000692.pdf

Reference39 articles.

1. Chimeric antigen receptor T cells for sustained remissions in leukemia;Maude;N Engl J Med,2014

2. Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia;von Stackelberg;J Clin Oncol,2016

3. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy;Fry;Nat Med,2018

4. Acute lymphoblastic leukaemia in 2017: immunotherapy for ALL takes the world by storm;Teachey;Nat Rev Clin Oncol,2018

5. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia;Maude;N Engl J Med,2018

Cited by 143 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early predictive factors of failure in autologous CAR T-cell manufacturing and/or efficacy in hematologic malignancies;Blood Advances;2024-01-11

2. Clinicopathologic features of relapsed CD19(−) B‐ALL in CD19‐targeted immunotherapy: Biological insights into relapse and LILRB1 as a novel B‐cell marker for CD19(−) B lymphoblasts;International Journal of Laboratory Hematology;2024-01-04

3. New monoclonal antibodies for the treatment of acute lymphoblastic leukemia;Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal;2024

4. Practice Preferences for Consolidative Hematopoietic Stem Cell Transplantation Following Tisagenlecleucel in Children and Young Adults with B Cell Acute Lymphoblastic Leukemia;Transplantation and Cellular Therapy;2024-01

5. Determinants of outcomes and advances in CD19‐directed chimeric antigen receptor therapy for B‐cell acute lymphoblastic leukemia;European Journal of Haematology;2023-12-17